Company profile
HUTCHMED (CHINA) LTD
NASDAQ:HCMBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SOVLEPLENIB | phase3 | — | 14 | active |
| AMDIZALISIB | phase2 | — | 5 | completed, terminated |
| RANOSIDENIB | phase1 | — | 4 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (115)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03903705 | phase1_2 | completed | 2019-04-25 | 2023-11-15 | Hutchmed | : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors |
| NCT06387082 | phase1 | recruiting | 2024-05-27 | 2027-10-08 | Hutchmed | A Clinical Study of HMPL-506 in Patients With Hematological Malignancies |
| NCT05318820 | — | completed | 2022-06-01 | 2022-07-31 | Hutchison Medipharma Limited | A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different Manufacturers |
| NCT02590965 | phase2 | completed | 2014-05-29 | 2015-08-07 | Hutchison Medipharma Limited | A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer |
| NCT02966171 | phase1 | terminated | 2017-01-01 | 2018-08-23 | Hutchison Medipharma Limited | A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies |
FDA applications (0)
No records yet.